Objective: This retrospective cohort study presents simulation models for analyzing toxicities of doxorubicin and docetaxel, both in combination of cyclophosphamide (AC and TC). It compared their side effects during postoperative chemotherapy of the treated Pakistani breast cancer patients. Study Design: It was retrospective study. Settings: Radiotherapy and Oncology Department, Allied Hospital, Faisalabad, Pakistan. Duration: Between September 2015 and September 2017. Methodology: 188 Patients out of 356 received TC (600 mg/m2 of cyclophosphamide, 75 mg/m2 of docetaxel) and 168 received AC (600 mg/m2 of cyclophosphamide,60 mg/m2 of doxorubicin). Using simulation and modeling the study presents two simulation models called SMG1SE, (Simulation Model for Side Effects listed in Group 1) and SMG2SE (Simulation Model for Side Effects listed in Group 2). SMG1SE shows drugs toxicity based on side effects, listed in group 1 including muscles pain, mild anemia, moderate anemia, blood transfusion, weight loss, and hands burning. SMG2SE shows toxicity based on side effects, listed in group 2 including vomiting, change in taste, sores in throat, diarrhea, tiredness, and dizziness. Results: At a=0.05, chi-squared test was used for statistical analysis. No significant difference was observed between the percentages of patients with extreme tiredness, stability, mild anemia, vomiting, and diarrhea for P-value remained>0.05. Though, AC(P-value<0.05)was found less toxic by 25.7%, 22.6%, 25.3%,20.8%,16.4%, and 12.4% and compared to TC for muscle pain, changes in taste, burning hands, moderate anemia, needing blood transfusion, and change in hemoglobin level, respectively, but TC was found less toxic by 32.5%, 26.3%, and 52.9% for weight loss, sores in throat and mouth, and dizziness respectively. Conclusion: At 24 months, AC remained less toxic than TC.